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Abstract
Aspergillosis is a fungal disease due to Aspergillus molds that can affect both humans and
animals. As routine diagnosis remains difficult, improvement of basic knowledge with
respect to its pathophysiology is critical to search for new biomarkers of infection and new
therapeutic targets. Large-scale proteomics allows assessment of protein changes during
various disease processes. In the present study, mass spectrometry iTRAQ® (isobaric tags
for relative and absolute quantitation) protocol was used for direct identification and relative
quantitation of host proteins in diseased fluids and tissues collected from an experimental
rat model challenged with Aspergillus, as well as in blood obtained from naturally-infected
penguins. In all, mass spectrometry analysis revealed that proteome during aspergillosis
was mostly represented by proteins that usually express role in metabolic processes and
biological process regulation. Ten and 17 proteins were significantly 4.0-fold overrepre-
sented in blood of Aspergillus-diseased rats and penguins, respectively, while five and 39
were negatively4.0-fold depleted within the same samples. In rat lungs, 33 proteins were
identified with positive or negative relative changes versus controls and were quite different
from those identified in the blood. Except for some zinc finger proteins, kinases, and histone
transferases, and while three pathways were common (Wnt, cadherin and FGF), great inter-
species variabilities were observed regarding the identity of the differentially-represented
proteins. Thus, this finding confirmed how difficult it is to define a unique biomarker of infec-
tion. iTRAQ® protocol appears as a convenient proteomic tool that is greatly suited to ex
vivo exploratory studies and should be considered as preliminary step before validation of
new diagnostic markers and new therapeutic targets in humans.
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Introduction
Aspergillosis is a fungal airborne infection due to saprophytic ubiquitous molds that belong to
Aspergillus genus [1]. It is responsible for several distinct respiratory diseases in both animals
and humans. For example, aspergillosis is subacute or chronic in penguins under human care
in zoos [2], and its incidence was estimated to 20.2% in a rehabilitation center in Brazil [3]. In
such birds, it implies adaptive immunity and develops progressively at the inner surface of air
sacs [2]. In humans, the invasive form is rather encountered during severe neutropenia and is
more acute; its incidence raised to5% after intensive chemotherapy or allogenic hematopoi-
etic stem-cell transplantation [4]. Invasive aspergillosis causes high morbidity, and mortality
rates have been estimated as 30–70%, depending on the underlying medical conditions, the
site of infection and the degree of dissemination [5]. The Aspergillus species of the Fumigati
section are those which have been primarily isolated from most of the human and animal clini-
cal specimens. Species belonging to Flavi, Nigri or Terrei sections have been less frequently cul-
tured [1].
Therapeutic failures during aspergillosis are partly due to the delay for establishing an accu-
rate diagnosis, especially since the current laboratory diagnostic options are not numerous and
display several limitations [1]. Detection of galactomannan antigen, i.e. a cell wall polysaccha-
ride produced during hyphal growth, in patient blood by ELISA assay has made a major con-
tribution to the diagnosis in the last ten years. It is now considered as a pivotal mycological
parameter to achieve diagnosis of aspergillosis [6], but it sometimes suffers from a poor speci-
ficity in cases of concomitant administration of β-lactam antibiotics or polyvalent immuno-
globulins [7]. Furthermore, the galactomannan test may be falsely negative in patients from
clinical departments other than haematology: in a French cohort reporting 424 cases of asper-
gillosis, 68.7% and 69.1% serum samples were positive for individuals with acute leukaemia or
allogenic hematopoietic stem-cell transplantation, versus 25.8% and 36.4% for patients with
solid-organ transplantation or systematic inflammatory diseases, respectively (P<0.001) [5].
Furthermore in veterinary medicine, detection of galactomannan is not reliable at all in some
birds, especially in raptors or parrots [8]. (1–3)-β-D-glucan, i.e. a fungal cell wall component,
which has been recently incorporated into the European Organization for Research and Treat-
ment of Cancer / Mycoses Study Group (EORTC/MSG) mycological criteria for invasive
aspergillosis diagnosis in human patients, is a serum pan-fungal biomarker with a high nega-
tive predictive value, but with no specificity for Aspergillus genus [6]. The Aspergillus-specific
lateral flow device, which is based on the JF5 antibody, detects an extracellular glycoprotein
antigen secreted during active growth of Aspergillus spp. This point-of-care device permits
rapid testing of easily obtainable specimens and has shown promising results in various stud-
ies, but it still needs further validation steps [9]. Quantitative polymerase chain reaction
(qPCR) has not been standardized yet, and thus is nowadays not considered as a pivotal diag-
nostic criterion, although its potential benefit has been several times underlined [10]. Colony-
forming unit (CFU) counting based on in vitro fungal cultures is not reliable enough to esti-
mate the actual Aspergillus burden, because it does not reflect the total amount of viable, dor-
mant and dead fungus within the tissue or the fluid that is investigated [1,11]. Detection of
anti-Aspergillus antibody is not recommended in highly immunocompromised patients and is
rather reserved for the indirect diagnosis of chronic aspergillosis [12]. It is systematically posi-
tive in penguin blood whatever the clinical status [13]. As alternatives, new biomarkers of
aspergillosis are therefore needed, and it is likely that their definition will occur through the
improvement of basic knowledge about pathophysiology. Study of the specific host response
during aspergillosis may be able to provide such information.
iTRAQ protocol for investigation of aspergillosis
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In last decade, transcriptomics and proteomics have been largely used for addressing signif-
icant protein changes within various diseased organisms or pathologic fluids [14]. However,
transcriptome profiling has limitations, because mRNAs and levels of corresponding proteins
are not systematically linked due to post-translational modifications [15]. In addition to their
capacity for accurate peptide characterization, some innovative mass spectrometry (MS) tools
are now able to directly quantitate the relative amount of proteins identified within fluid or tis-
sue, regardless if they are or are not post-translationally modified. For instance, the iTRAQ1
(isobaric tags for relative and absolute quantitation) protocol is a large-scale isobaric labeling
method of unbiased profiling to identify and to determine the change in levels of proteins
from different multiplexed sources within a single experimental run [16]. While generating no
interference with peptide mass determination, iTRAQ1 technique uses stable isotope-tagged
molecules that can be covalently bonded to the N-terminus and side chain amines of trypsin-
digested peptides [17]. It requires no preliminary labor-intensive steps of protein separation,
like two-dimensional gel (2D-gel) electrophoresis, that inevitably implies a risk of information
loss [14,18], and which is less sensitive [18]. Moreover, iTRAQ1 protocol allows addressing
protein modifications including those induced during pathologic processes leading to the for-
mation of post-translationally modified proteins, as well as proteolytic fragments that may be
pathogenic for tissue-invasive disease such aspergillosis.
Through application based on iTRAQ1 protocol, the goal of this study was to bring new
insights into host protein responses against Aspergillus, using an experimental murine model
of aspergillosis, as well as samples obtained from naturally-infected birds. The overall objective
relies in investigating the pathophysiology of aspergillosis in order to suggest possible host bio-
markers of infection, so that later facilitating diagnosis in birds, for which there are no ade-
quate diagnostic assays, and perhaps to widen similar perspectives in humans for which rapid
diagnosis is still sub-optimal to date. We are also searching for new therapeutic targets to
enhance the anti-Aspergillus response.
Material and methods
Study population: Animal models of infection
Inclusion and samples. Blood samples and lung parenchyma specimens were obtained
from 6–8 week-old male neutropenic rats (Rattus norvegicus, N1 = 46). Previously, rats had
been immunocompromised by intraperitoneal injections of cyclophosphamide (Endoxan
10001, Baxter, Guyancourt, France) repeated every four days, and had been intra-tracheally
challenged with either 1 mg/kg bacterial lipopolysaccharides (Salmonella enterica Serovar
Typhimurium 2 mg/mL LPS, Sigma-Aldrich, Saint-Quentin-Fallavier, France) (n1 = 14) or
with 1.0x106 A. fumigatus conidia (strain No. BRFM 1827, collection WFCC-MIRCEN World
Data Centre for Microorganisms, Marseille, France) (n1’ = 32), according to the experimental
model previously described [19,20]. The animals had free access to sterile water supplemented
with 750 mg/L tetracycline antibiotic (Sigma-Aldrich, Saint-Louis, MO, U.S.A.) to prevent
possible opportunistic bacterial infections, and with 300 mg/L acetaminophen (Efferalgan
1501, Bristol-Myers-Squibb, New York, NY, U.S.A.) as a painkiller.
Furthermore, routine blood samples were collected into BD PST 0.5 mL-Microtainer1 tubes
(Becton-Dickinson, Le Pont-de-Claix, France) from African penguins (Spheniscus demersus, N2 =
112) under human care in seven facilities in the United States of America (U.S.A.).
Upon arrival to the laboratory in charge of the mass spectrometry experiment (University
of Miami, FL, U.S.A.), all blood samples were centrifuged for 10 minutes (min) at 3000 g and
stored at -80˚C before being utilized for testing. The whole lungs were placed in sterile con-
tainers and flash frozen in liquid nitrogen before protein extraction.
iTRAQ protocol for investigation of aspergillosis
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Case definitions. For the rat protocol, blood sampling at baseline, i.e. before any tracheal
challenge, defined the healthy status (blood collection by puncture of the lingual vein into
1.5mL-serum tubes). Rats inoculated with LPS were considered as inflammatory controls. For
the rats that were experimentally-inoculated with A. fumigatus conidia, the diagnosis of
“proven” aspergillosis was established when fungal elements were observed on histopatholog-
ical slides of lungs prepared at date of death or at time of sacrifice [19]. The latter was decided
when rats began to present deleterious clinical signs consistent with the development of asper-
gillosis, i.e. according to a discomfort scale which was checked thrice daily and scored from 1
to 6 on the basis of appearance changes (e.g. dirty nose, red-rimmed eyes, ruffled fur, extreme
pallor), behavior changes (e.g. gasping, wheezing, prostration, instability), reaction to stimuli
and variation of body weight,. . . Score 1 was consistent with no discomfort; score 2, minor dis-
comfort; score 3, poor discomfort; score 4, serious discomfort; score 5, severe discomfort; and
score 6, death. Score 3 was set as the endpoint; it encompassed respiratory troubles, prostra-
tion, bleeding,. . . [21]. For control rats, the sacrifice was scheduled one to two days after LPS
instillation, when the inflammatory reaction was assumed to be maximal [14]. Practically, rats
were killed after anesthesia with 5% isoflurane (Aeranne1, Baxter, Deerfield, IL, U.S.A.) by the
intraperitoneal injection of 0.5 mL of 2.5% thiopental (Nesdonal1, Sanofi-Aventis, Mon-
trouge, France). In cases histopathology was non-contributive, the diagnosis of “probable”
aspergillosis was retained in rats when were present at least two positive biomarkers among
the following ones: galactomannan antigen in the blood with index > 0.5 in accordance with
the kit manufacturer’s instructions (EIA Platelia Aspergillus1, Bio-Rad, Marnes-la-Coquette,
France) (index is defined as the ratio of the optical density value of the sample to the value of a
standard containing 1 ng of galactomannan); galactomannan antigen in the bronchial-alveolar
lavage fluid (BALF) with index > 1.0; or 48h fungal culture with 5 CFU per 100 μL BALF
pellet that had been inoculated onto Sabouraud-dextrose agar with gentamicin and chloram-
phenicol (ThermoFisher Scientific, Dardilly, France) [14]. If histopathology was negative and
only one or less of the three abovementioned biomarkers was present in Aspergillus-challenged
rats, the corresponding samples were considered as equivocal and then excluded from the sub-
sequent analysis. According to the aforementioned restrictions, we were able to collect 18
blood samples at baseline, 12 after LPS-challenge and 14 after Aspergillus-challenge. Ten and
16 lung parenchyma specimens were also obtained from control and infected animals, respec-
tively. Besides, there were no expected deaths due to other types of infection in this protocol,
as confirmed by sterile cultures on media specifically dedicated to bacterial growth (chocolate
agar PolyViteX1, BioMe´rieux, Craponne, France).
Aspergillosis classification in penguins was derived from the definition utilized in human
medicine [6,10]. The definitive diagnosis of “proven” fungal infections was based upon histo-
pathologic evidence [1]. The diagnosis of “probable” aspergillosis was retained upon positive
fungal culture (from any tissues that were assumed to be relevant for mycological investiga-
tions, i.e. primarily lungs or air sacs) in conjunction with clinical examination findings (e.g.
dyspnea, wheezing, gasping, stridor, open-mouth breathing, coughing, changes in vocaliza-
tions,. lethargy, anorexia, weight loss, . . .) or imaging investigations (celioscopy and/or X-radi-
ography performed for 40.9% birds) and/or any medical records which corroborated the
diagnosis. Since galactomannan antigen detection has been shown to be unreliable in birds, it
was not considered herein to be a pivotal parameter for the diagnosis of “probable” aspergillo-
sis in penguins [8,22]. Samples obtained from birds with clinical signs of aspergillosis, but with
neither positive fungal cultures nor imaging findings available, remained in the study if the
animal responded well to antifungal treatment and had detectable anti-Aspergillus antibodies
in blood associated with marked changes in the protein electrophoretogram performed on the
Spife 30001 electrophoresis analyzer (Helena Labs, Beaumont, TX, U.S.A.) [13]. Detection of
iTRAQ protocol for investigation of aspergillosis
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anti-Aspergillus antibodies was conducted via a previously described ELISA technique using
bulk Aspergillus ID antigens made of pooled mycelial-phase culture filtrates of Aspergillus spe-
cies (IMMY, Norman, OK, U.S.A.) [13]. These cases were therefore considered “possible”
diagnosis. The samples obtained from penguins with equivocal context of aspergillosis were
excluded. Animals with no apparent clinical signs were considered healthy controls, while
those undergoing miscellaneous non-Aspergillus-related processes, including other infections,
were classified as inflammatory controls. In all, 38 samples were collected from 34 diseased
penguins at time of aspergillosis diagnosis (for two penguins, sampling were performed in
triplicate). Fifteen follow-up samples were obtained for 14 of them, in average 55.6 ± 31.5 days
after the initial diagnosis (and thus defined the “convalescent” group when clinical improve-
ment was noticed and/or long-term antifungal therapy was given). Ninety-eight samples were
drawn from 78 other penguins, including 53 healthy birds and 25 non-Aspergillus inflamma-
tory controls.
Proteomic analysis
Preliminary extraction of proteins from tissues. After thawing, rat lungs were manually
crushed and soaked in 1% sodium dodecyl sulfate (SDS) extraction buffer and then homoge-
nized for two min. Homogenates were centrifuged at 12,000 g, and the supernatants were
boiled at 95˚C for 5 min and neutralized with 100 mM Tris, pH10 during 10 min. Cold acetone
was added and incubated on ice for 15 min. After centrifugation, the pellets were dried in an
Eppendorf Vacufuge1 concentrator (ThermoFisher Scientific, Waltham, MA, U.S.A.), and re-
suspended in 20 μL water and 10mM dithiothreitol. At that point, all the lung protein extracts
were processed for proteomic study as with the blood samples described below.
Distribution into distinct aliquot groups. For each animal species, blood samples or tis-
sue protein extracts were pooled into single tubes according to the medical group they belong
to, by including 1000 μg protein for each in order to constitute distinct representative aliquots.
For instance for the rat protocol, the five following representative groups were defined: in
blood at baseline (i.e. before the experimental challenge), in blood after inflammation-chal-
lenge with LPS, in blood after Aspergillus-challenge, in lung parenchyma after LPS inflamma-
tion-challenge, in lung parenchyma after Aspergillus-challenge. For the penguins, the four
following groups were constituted by pooling separately the blood samples for clinically-nor-
mal animals, non-Aspergillus inflammatory controls, Aspergillus-diseased animals, and conva-
lescent subjects (see definition above).
Pre-processing step with iTRAQ1-tags labeling. Protein enrichment was completed in
each of the pooling tubes using the Pierce Albumin / IgG removal1 kit (ThermoFisher Scien-
tific, Waltham, MA, U.S.A.) that allows for depletion of overrepresented proteins like albumin
or immunoglobulins [23], as demonstrated in previous works with mammal and chicken sam-
ples [14]. Total protein was quantified in each pool by the Pierce BCA Protein assay1 kit
(ThermoFisher Scientific, Waltham, MA, U.S.A.), according to the manufacturer’s instruc-
tions [23]. Then, 100 μg of each pool was incubated with 30 μL dissolution buffer of 0.5 M
triethylammonium bicarbonate (Sigma-Aldrich, Saint-Louis, MO, U.S.A.) at pH 8.5, and
thereafter treated with 2% SDS-denaturant solution. One microliter of tris-(2-carboxyethyl)
phosphine-reducing reagent was added, followed by vortex-shaking for 1 min, centrifugation
at 18.000 x g for 5 min and incubation at 60˚C for 1 h. After another step of shaking and centri-
fugation, 84 mM iodoacetamide was added for a 30 min-long incubation in the dark at room
temperature. Freshly prepared 0.1 μg/μL sequencing grade modified trypsin was then mixed
with each sample, and digestion was carried out at 37˚C during 30 min. Thereafter, 1 μL tryp-
sin was added to continue digestion overnight. The samples were dried in an Eppendorf
iTRAQ protocol for investigation of aspergillosis
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Vacufuge1 concentrator, then reconstituted with 30 μL dissolution buffer. Every tube was
mixed with one unique iTRAQ1 reagent vial (Sigma-Aldrich, Saint-Louis, MO, U.S.A.) and
reconstituted in isopropanol, according to the manufacturer’s recommendations. For instance
for rats, the tube containing all the blood samples pooled at baseline was mixed with the
113-iTRAQ1 reagent; this containing the blood samples from control rats undergoing LPS
inflammation with the 114-reagent; this containing the blood specimens from Aspergillus-dis-
eased rats with the 115-reagent; this containing the pool of lung protein extracts from LPS-
control rats with the 116-tag; and the aliquot containing the pool of lung protein extracts from
Aspergillus-diseased rats with the 117-reagent. Thereafter, the contents of all these iTRAQ1
reagents-labelled tubes were combined into one single tube per species, vortexed for 1 min,
and centrifuged at 18,000 g for 5 min. The multiplexed specimen was totally dried by centrifu-
gal vacuum concentration as above. The same procedure was separately applied for all of the
penguin samples, according to the repartition into distinct clinical groups that were defined
above.
Processing steps by mass spectrometry iTRAQ1 protocol. The aliquots of the two mul-
tiplexed iTRAQ1 tubes (one for all the rats and one for all the penguins,) were separately re-
suspended in 2% acetonitrile and individually loaded onto an ultra-high performance liquid
chromatographic (UHPLC) method. UHPLC analysis was conducted according to the manu-
facturer’s indications in an Easy Nano LC 10001 model (ThermoFisher Scientific, Waltham,
MA, U.S.A.), where a 75 μm i.d. x 15 cm column, packed with Acclaim PepMap1 RSLC C18-
2 μm 100Å column (ThermoFisher Scientific, Waltham, MA, U.S.A.) was in-line connected to
a Acclaim PepMap1 100 75 um x 2 cm, nanoviper C18-3 μm 100 Å pre-column (Thermo-
Fisher Scientific, Waltham, MA, U.S.A.). Peptides were eluted following a 75 min gradient
from 2% to 98% acetonitrile (ThermoFisher Scientific, Waltham, MA, U.S.A.) in UHPLC
water at a flow of 350 nL/min. Then, the eluates were individually run in a QExactive1 Orbi-
trap mass spectrometer (ThermoFisher Scientific, Pittsburg, PA, U.S.A.) in a data-dependent
mode, with an automatic gain control target of 1.0x106 for full MS at 70,000 resolution, and of
2.0x105 for dd-MS2 at 17,500 resolution in positive mode. The detection performance of this
QExactive1 Orbitrap were previously evaluated as follows: high resolving power of 140,000
full width at half maximum, defined at m/z 200, and elevated resolution at Δm/z = 0.001, with a
50–4,000 m/z range. The isolation window was fixed to 1.5 m/z with normalized collision
energy of 28 eV, underfill ratio of 1.0%, and dynamic exclusion of 3.0. First mass was fixed to
103 m/z. Each aliquot was tested in triplicate.
Mass spectrometry data analysis and identification/quantitation of host proteins. The
bioinformatics analysis was performed using the Proteome Discoverer1 software (Thermo-
Fisher Scientific, Pittsburg, PA, U.S.A.). Specific SwissProt1 reviewed non-redundant data-
bases (http://www.uniprot.org/uniprot/) were used for the analysis of rat (according to the
following genera: Rattus, Fukomys, Heterocephalus, Niviventer, Thryonomis, Ctenodactylus,
Malacomys, Spalax, Ondrata, and Mus) and penguin (Spheniscus, Aptenodytes, Pygoscelis) pro-
teomes using the Sequest1 HT search engine (Washington, DC, U.S.A.) [24]. The parameters
of the study set trypsin as the enzyme used for digestion, with a maximum number of missed
cleavage sites of two, 10 ppm as precursor mass tolerance, and 0.02 Da for fragment mass toler-
ance. Alkylation, as well as N-terminal / lysine modifications and dynamic iTRAQ1 modifica-
tions were selected as fixed, monoisotopic mass was chosen, and threshold for expected ion
score cut-off was inferior to 0.05, 95% confidence. Maximum value for delta-correlation was
set to 0.05. False discovery rate target value was 0.01 for strict rate and 0.05 for relaxed one,
considering the q-value as a validation reference. At least one unique peptide was necessary for
each protein identified. Median intensities were used for normalization, and outliers were
removed automatically. Search results were passed through additional filters to exclude
iTRAQ protocol for investigation of aspergillosis
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unlabeled proteins before exporting the data. Protein identification was achieved using a
Bayesian algorithm where matches were characterized by an expectation score, which repre-
sents an estimate of the number of matches that would be expected in that database [18].
At the quantification level, the analysis included -means clustering, i.e. supervised and heu-
ristic algorithm, for both protein and peptide quantitation ratios. The software actually worked
by grouping proteins, based on the peptide spectral matches (PSMs). Then, a customized ratio
was calculated for every protein group as the median of all PSMs included in the protein
group. Only ratios with P< 0.05 and only fold-changes 2.0 across three aliquot replicates
were used to determine up- or down-regulated proteins [25].
Validation assays
In order to confirm some findings of the MS analysis, the levels of Wingless integration site-1
(Wnt1) inducible signaling pathway protein 1 (WISP-1) levels were measured in distinct
blood samples of the rat model using the Rat WNT1 Inducible Signaling Pathway Protein 1
ELISA1 kit (MyBioSource, San Diego, CA, U.S.A.) [26], according to the manufacturer’s
instructions. Ten samples of each group of the protocol were tested simultaneously in
duplicate.
The levels of basic fibroblast growth factor (bFGF) were tested in the supernatants of the
lung homogenates by the means of the RayBio1 Rat bFGF ELISA kit (RayBiotech, Norcross,
GA, U.S.A.), tuning the manufacturer’s recommendations to that of cell culture media [27].
Ten samples of each group of the rat protocol were tested simultaneously in duplicate.
Statistical analysis
Statistical analyses were performed using XLStat1 v.2016.6.04 software (Addinsoft, Paris,
France). Missing data, e.g. when the total volume of sample was insufficient to complete all the
analyses, were managed by the method of mean imputation. Mann-Whitney, Chi-squared and
Kruskal-Wallis tests were applied. The α-risk was adjusted at 0.05.
Regarding specifically the iTRAQ1 data, we based inference on one-way analysis of vari-
ance (ANOVA) models, conducted on one protein at a time [28], combining both normaliza-
tion, i.e. bias removal, and assessment of differential protein expression in a single model fit to
the collection of reporter-ion peak areas, i.e. corrected for isotopic overlap, from all observed
tandem mass spectra. Principal component analysis (PCA) modeling was applied to facilitate
interpretation of the multivariate proteome dynamics dataset [29]. Data were z-scored prior to
model building.
To perform enrichment analysis on gene sets that were found up- and down-regulated dur-
ing aspergillosis, Gene Ontogeny (GO) base (http://www.geneontology.org/) was used for
every model. The following species names were selected on GO base: Rattus norvegicus for the
rats, and Gallus gallus for the penguins (because of no specific database available for any pen-
guin genera). The annotation data set used for the bioinformatic analyses were extracted by
overrepresentation test from PANTHER classification system version 11.1 (released 2016-10-
24) [30]. Bonferroni correction was used for multiple testing during expression data analysis.
Ethics
The authors applied the regulations of Declaration of Helsinki. They complied with the BRISQ
guidelines.
The rat model of invasive aspergillosis was approved by the General Direction for Research
and Innovation, French Ministry of Higher Education and Research through the accreditation
iTRAQ protocol for investigation of aspergillosis
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number No. 01901.01, and by the Ethics Committee for Animal Experimentation of the Val-
de-Loire region through the accreditation number No. C37-261-3 [14].
All the blood specimens from penguins utilized in this work were samples banked after rou-
tine veterinary assessments. Investigations in penguins were approved by the African Penguin
Species Survival Plan (SSP) of the Association of Zoos & Aquariums (AZA) program and by
the staff veterinarians in each of the submitting facilities.
Informed consent is not applicable.
Results
Description of animal and patient populations
In rats, the mean index for galactomannan antigen in blood was 0.1 ± 0.1 at baseline. After
experimental inoculation with Aspergillus, the mean measure at time of death was 2.8 ± 2.9 in
blood and 3.2 ± 2.4 in BALF, while histopathology was positive in 82.6% cases. In control rats,
the mean measure for galactomannan antigen was estimated at 0.2 ± 0.1 in blood and 0.7 ± 0.4
in BALF, whereas histopathology observation was systematically negative for fungus. Fungal
cultures showed an average of 28.4 ± 13.7 CFU/100 μL BALF pellet in Aspergillus-challenged
rodents versus 0.0 ± 0.0 CFU in controls. Eight blood samples and three lung protein extracts
were excluded from the analysis as they did not fulfill the inclusion conditions.
Characteristics of included penguins are detailed in Table 1. Measurement of galactoman-
nan antigen in blood displayed the following mean values: 0.5 ± 1.3 and 0.3 ± 0.3 indexes for
Aspergillus-diseased penguins and inflammatory controls, respectively. There were no differ-
ences for anti-Aspergillus antibody titers between cases and controls (P>0.05). In Aspergillus-
diseased penguins, α2- and β-globulins were significantly increased versus controls (P<0.05),
while albumin / globulin ratio was decreased (P<0.01). Eight penguin blood samples were
rejected, because they did not meet the inclusion criteria.
Proteomic analysis
A summarizing scheme of the iTRAQ1 protocol carried out in the experimental rat model is
shown in Fig 1 (lung parenchyma was not sampled at baseline to avoid sacrificing healthy ani-
mals before intra-tracheal challenge) (Fig 1). Globally, the technical principle was the same in
penguins. Overall, large-scale MS analysis achieved identification of 7,858 proteins in rat
blood samples, 4,430 in rat lungs, and 6,436 in penguin blood specimens. Significant quantita-
tive changes concerned a protein moiety equal to 0.6%, 1.4% and 3.0% species proteome in rat
blood, rat lung and penguin blood, respectively (Fig 2A; S1 and S2 Tables).
Protein changes in the experimental rat model. In rat blood, 148 proteins
were 2.0-fold differentially-represented (negatively or positively) after Aspergillus-inocula-
tion vs. LPS-challenge (Fig 2A; S1 Table). They mostly corresponded to proteins with binding
function (43.8%) and catalytic activity (37.5%) and were involved in cellular process (30.9%)
(Fig 2B). Among these 148 proteins, 71 were overrepresented. Ten were massively superabun-
dant, i.e. 4.0-fold increased (Table 2, Fig 3), and were confirmed for seven by comparison
with blood samples collected in healthy rats at baseline, but only moderately for the nucleolar
GTP-binding protein 2, the cytosol aminopeptidase, and the anillin actin-binding protein
(3.9-, 1.4-, and 2.4-fold increase) (Table 2). In comparison with rat whole proteome, 28 differ-
ent protein classes appeared significantly enriched during experimental aspergillosis, including
defense proteins, regulators of proteases, nucleases / helicases, phosphatases / kinases, hydro-
lases and deacetylases (Fig 2E). Bioinformatic analyses indicated that they were primarily
involved in signaling pathways via cadherin and Wnt (wingless integration site protein), lipid
and nucleobase metabolism, and in coagulation (Fig 2F, Table 3). Based on ELISA assay, Wnt1
iTRAQ protocol for investigation of aspergillosis
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inducible signaling pathway protein 1 (Wisp1) was confirmed globally overrepresented in
blood of 10 Aspergillus-diseased rats vs. control rats at baseline or after LPS-challenge,
1,052.4 ± 257.6 pg/mL vs. 450.7 ± 128.9 pg/mL or 609.7 ± 134.6 pg/mL, respectively (P<0.05)
(Fig 4A). Five proteins were more than 4.0-fold decreased vs. LPS-challenged controls, and
two of them were also significantly lowered vs. healthy rats: long-chain-fatty-acid-CoA ligase 1
and HMG box transcription factor BBX isoform 1 (Fig 3). Notably, the major protein changes
aforementioned were confirmed in a subset composed of eight distinct rat blood samples
(from four LPS-challenged controls vs. four Aspergillus-challenged cases) that were individu-
ally treated by iTRAQ1 protocol and compared to each other (data not shown).
In rat lungs infected with Aspergillus, 325 proteins were differentially over- or under-repre-
sented vs. LPS inflammatory controls (Fig 2A; S1 Table). Among them, 37.2% and 35.3% had
catalytic and binding activities, whereas 28.1% and 21.2% were in charge of cellular and meta-
bolic processes (Fig 2C), respectively. One hundred eighty-two proteins were at least 2.0-fold
increased, but only 14 were more than 4.0-fold increased (Fig 3; Table 4). Notably, although
none of them was also found overrepresented in rat blood in the same time, similar or
Table 1. Characteristics of the penguins included in the study. The assignment was made according to the case defi-
nition for diagnosis of aspergillosis (for details, see Material &Methods section).
Mean (± SD) or Number (%), [95%confidence interval]
Study population of the penguin cohort (N2 =
112)
Aspergillus-diseased cases (n2 = 34) Controls‡ (n2” = 78)
Age (years) 7.6 (± 7.1), [5.4–9.8] 11.6 (± 9.9), [9.4–13.9]
Sex (male) 21 (61.8%), [48.3–77.2%] 40 (51.3%), [40.8–
63.1%]
Clinical signs
respiratorya 23 (67.6%), [51.9–81.5%] 9 (11.5%), [5.0–17.5%]
generalb 26 (76.5%), [63.7–90.1%] 19 (24.4%), [16.0–
33.0%]
neurologicalc 4 (11.8%), [2.3–23.3%] /
Protein electrophoresisφ
albumin / globulin ratio 0.4 (± 0.4), [0.3–0.6] 0.8 (± 0.5), [0.7–0.9]
albumin (g/dL) 1.4 (± 0.8), [1.0–1.8] 2.0 (± 0.5), [1.9–2.1]
α1-globulins (g/dL) 0.1 (± 0.0), [0.1–0.1] 0.2 (± 0.1), [0.1–0.2]
α2-globulins (g/dL) 1.2 (± 0.5), [1.0–1.5] 0.8 (± 0.3), [0.6–0.9]
β-globulins (g/dL) 1.8 (± 0.6), [1.5–2.0] 1.6 (± 0.8), [1.2–1.8]
γ-globulins (g/dL) 1.4 (± 0.8), [1.0–1.7] 2.0 (± 1.5), [1.6–2.4]
Findings for aspergillosis diagnosis
suggestive imaging 11 (32.6%) [18.1–45.6%] 2 (2.6%) [0.0–4.8%]
positive in vitro culture 2 (5.9%) [0.0–14.3%] /
anti-Aspergillus antibody ELISA optical densityφ 1.8 (0.3%) [1.6–1.9] 1.9 (0.3%) [1.8–2.1]
positive histopathology observation 5 (14.7%) [5.1–26.7%] /
Response to antifungal treatment (positive) 28 (82.6%) [68.5–93.7%]$ /
‡ included samples from clinically-normal penguins (n = 53) and from control cases undergoing arthritis (n = 6),
anemia (n = 4), malaria (n = 3), carcinoma (n = 2), or other miscellaneous causes of inflammation (n = 10)
a i.e. dyspnea, wheezing, gasping, stridor, open-mouth breathing, coughing, changes in vocalizations
b i.e. lethargy, anorexia, weight loss, lack of appetite, sternal recumbency, regurgitation
c i.e. ataxia, opistophonos, torticollis, limb paresis, blindness, behaviour changes
φ according to Cray et al. [13]
$ two penguins were lost to follow up
https://doi.org/10.1371/journal.pone.0200843.t001
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overlapping pathways were promoted in both sample types: for example, lipid metabolism via
cholesterol and pyruvate biosynthesis, coagulation, cadherin and Wnt signaling pathways
(Table 3). As a confirmation, ELISA assay showed individual levels for Wnt1 inducible signal-
ing pathway protein 1 (Wisp-1) that were insignificantly higher in lung homogenates from
Aspergillus-diseased rats than in LPS-challenged rats, 999.5 ± 228.6 pg/mL vs. 705.1 ± 137.8 pg/
mL (P>0.05) (Fig 4B). Likewise, the fibroblast growing factor (FGF) pathway was found
2.0-fold enriched in Aspergillus-diseased rats vs. those challenged with LPS, and this trend was
confirmed through the ELISA assay, 440.0 ± 133.1 pg/mL vs. 233.2 ± 122.2 pg/mL (P>0.05)
(Fig 4C). Overall, relative enrichment applied to 55 distinct protein classes: transporters,
nucleic acid binding, ion-channel, serine protease inhibitor, and helicase families were primar-
ily represented in rat lungs. In addition, 143 proteins were found at least 2.0-fold negatively
changed vs. LPS-inflammatory rat lungs. Interestingly, D-amino-acid oxidase protein, which
was 4.9-fold decreased in lungs of Aspergillus-challenged rats, was also significantly lowered in
blood by 2.1-fold (Tables 3 and 4). Likewise, olfactory receptor and coiled-coil domain-con-
taining protein were found moderately low in Aspergillus-diseased rat lungs vs. LPS-challenged
control lungs, reduced by 2.4- and 2.7-fold, respectively, and also in blood, 4.7- and 2.9-fold,
respectively.
Large protein changes in penguin samples. In blood collected from penguins with asper-
gillosis, 468 proteins were differentially over- or under-expressed vs. non-Aspergillus
Fig 1. Example of study design for iTRAQ1 protocol in the experimental rat model of invasive aspergillosis. Upper right panel, the iTRAQ1 reagent is designed as an
isobaric stable tag consisting in a charged reporter group that retains charge (N,N-dimethylpiperazine), a peptide reactive group (N-hydoxy-succinimide) that is amide-
linked to the N-terminus and the ε-amino side chains of all the peptides got from prior tryptic digestion, and a neutral balance portion (carbonyl) to maintain an overall
mass of 305 kDa by the means of differential isotopic enrichment with 13C, 15N and 18O atoms [33]. The selection of the reporter region in the low mass area enables
keeping the additive mass to the fragments as negligible as possible in order to minimize any side effect during chromatographic separation and to avoid any interference
with other fragment ions during mass spectrometry analysis, thus allowing for the highest degree of confidence; Main panel, after intra-tracheal challenge with bacterial
lipopolysaccharides (LPS) or Aspergillus fumigatus conidia, rat samples were pooled according to their clinical status: healthy controls at baseline before intra-tracheal
challenge in blood, non-Aspergillus inflammatory controls and Aspergillus-diseased cases, both in blood and in lung parenchyma for the last two groups [19,20].
Overabundant proteins, like albumin and immunoglobulins, were removed through a commercial kit before mass spectrometry analysis [23,56], and specific labelling
with individuals tags, ranging from 113-iTRAQ1 to 117-iTRAQ1 reagents, was then applied to each pooled aliquot [16]. The reporter-balance peptides remained intact,
so that for one given common protein, the five multiplexed rat samples had an identical m/z: the peptide fragments were equal, only the reporter ions were different.
Indeed, the precursor ions, and all the internal fragment ions, i.e. type b- and y-ions respectively, contain all five members of the tag set, but remain isobaric, i.e. the five
species have the same atomic mass but different arrangements. After collision in the QExactive1 Orbitrap mass spectrometry (MS) instrument, the five reporter group
ions appeared as distinct masses ranging between m/z 113–117, while the remainder of the sequence-informative b- and–y ions remain isobaric and their individual
current signal intensities were additive. The relative concentration of the peptides in every samples pool was then deduced from the relative signal intensities of the
corresponding reporter ions. Protein identification was achieved by comparison of the peptide sequences with Specific SwissProt1 reviewed non-redundant database
(http://www.uniprot.org/uniprot/) of Rattus norvegicus (rat) proteome using the Sequest1 HT search engine (Washington DC, U.S.A.). Abbreviations: b-ion, Precursor
ion; C, Carbon; Da, Dalton; MS, Mass spectrometry; m/z, Mass-to-charge ratio; O, Oxygen; N, Azote; y-ion, Internal ion; U.S.A., United States of America.
https://doi.org/10.1371/journal.pone.0200843.g001
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Fig 2. Global protein changes and Gene Ontology (GO, http://www.geneontology.org/) enrichment analysis within Aspergillus-diseased organisms versus
control conditions, according to the PANTHER classification system [30,57]. A—The bar chart indicates the absolute number of proteinsthat were found
positively or negatively 2.0-fold differentially-expressed amongst each species (S1 Table). The dots of the curve indicate the proportion of proteins, expressed in
percentages in comparison to the whole known proteome of each studied organism, that were positively or negatively 2.0-fold differentially-expressed during
aspergillosis; B–The multiple pie chart in the upper panel displays distribution of the molecular functions of all the proteins that were identified as positively or
negatively 2.0-fold differentially-expressed in rat blood during experimental aspergillosis vs. control rats challenged with bacterial lipopolysaccharide (LPS); the pie
chart of the lower panel shows the corresponding biological processes for the same proteins; C—Results for proteins that were positively or negatively 2.0-fold
changed in rat lung during experimental aspergillosis vs. control rats challenged with LPS; D—Results for proteins that were positively or negatively 2.0-fold
differentially represented in penguin blood during aspergillosis vs. control penguins undergoing non-Aspergillus inflammatory diseases; E–The overlaid area chart of
iTRAQ protocol for investigation of aspergillosis
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inflammatory controls (Fig 2A; S1 Table). Among them, 31.7% expressed binding activities,
whereas 29.1% and 26.2% were involved in cellular and metabolic processes (Fig 2D). Individ-
ually, 171 proteins were significantly overrepresented, including 17 more than 4.0-fold
increased, and 135 of them were confirmed vs. clinically-normal controls (Fig 3; Table 5). Pro-
tein enrichment applied to 63 families, including various transfer / carrier, receptor, nucleic
acid binding, nuclease, metalloprotease, and serine protease inhibitor proteins. Receptor and
apoptosis pathways, as well as signaling pathways via cadherin and Wnt, were overrepresented
during aspergillosis in comparison with physiological pathways of the whole proteome
(Table 3). While they were 4.4-, 2.5-, 2.5-, 2.2-fold overexpressed vs. non-Aspergillus inflamma-
tory controls, F-box/LRR-repeat protein 4, THAP domain-containing protein 1, histidine-
tRNA cytoplasmic ligase and AIM1 (absent in melanoma-1) protein were found also statisti-
cally overrepresented vs. convalescent penguins, 2.5-, 2.1-, 2.0- and 3.8-fold, respectively. Con-
versely, 297 proteins were found decreased in Aspergillus-diseased penguins in comparison
with non-Aspergillus inflammatory controls. The decrease was confirmed vs. clinically-normal
controls for 30 of the 39 proteins lowered by4.0-fold, and 13 were also found lowered vs.
convalescent penguins. These major protein changes were confirmed in eight distinct penguin
blood samples that were individually treated by iTRAQ1 protocol and compared to each
other (data not shown), e.g. the eukaryotic elongation factor 2 kinase was found 2.0-, 2.1-, 2.8-
and 2.6-fold overrepresented in the four diseased cases vs. the four healthy controls, while the
fragment of interleukin-17 receptor D was 5.4-, 7.6-, 6.3-, and 6.8- fold increased.
Discussion
In both human and veterinary medicine, routine diagnosis and curative treatment of aspergil-
losis continue to be very difficult [1]. For example, although Aspergillus galactomannan anti-
gen detection has nowadays been acknowledged as an important tool in neutropenic human
patients [6,31], the present work confirmed important diagnostic limitations regarding its reli-
ability in veterinary samples, since in this study only 23.1% of the Aspergillus-diseased pen-
guins had galactomannan index> 0.7. Overall, it is critical to search for new biomarkers of
aspergillosis in order to improve its diagnosis, and consequently to decrease the subsequent
morbidity and mortality by initiating rapid adequate antifungal therapy [32]. Pathophysiology
studies can bring new insights for such a purpose, as well as for suggesting new therapeutic
targets.
Through its great sensitivity, proteomics may contribute to the discovery of new markers of
aspergillosis [14]. In such a context, iTRAQ1 protocol appears as a convincing innovative
technique based on a ready-to-use affordable kit that allows a direct differential comparison of
proteomes [23,33]. Noteworthy, iTRAQ1 method is only programmed to make relative com-
parison of proteins that are detectable in all the analyzed samples. It means that this technique
cannot be used to detect protein(s) of pathogens that are supposed to be present only in
infected fluids/tissues and not in healthy specimens. It is also the reason why iTRAQ1 is rather
dedicated to investigate host protein changes [34]. Other molecular tools focused on pathogen
cell wall, intracellular components or extracellular secretome should be considered in order to
difference obtained by bioinformatic analyses revealed that blood protein enrichment during experimental aspergillosis in rats concerned 28 distinct protein classes,
including defense proteins like immunoglobulin superfamily and complement components, nucleases, various mRNA processing factors, helicases, cytokines, serine
protease inhibitors and protein phosphatases/kinases; F–The bar chart of difference obtained by bioinformatic analyses revealed that blood protein enrichment
during experimental aspergillosis in rats primarily concerned six different pathways: blood coagulation, cadherin signaling pathway, de novo purine biosynthesis,
pyruvate metabolism, tricarboxylic acid cycle, and Wnt signaling pathway. Abbreviation: GO, Gene ontogeny;⇑, positive enrichment>10% gene hit against total
biological process hits; +, negative enrichment>10% gene hit against total biological process hits; = , positive or negative enrichment<10% gene hit against total
biological process hits.
https://doi.org/10.1371/journal.pone.0200843.g002
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Fig 3. Forest plot diagram showing respective levels for the proteins that were found to be significantly overrepresented or under-
represented in each animal species, in comparison with control conditions. For better clarity, only the very abundant (5.0-fold increased vs.
controls) or very depleted proteins (5.0-fold decreased) are shown. Results are presented gathered according to protein functions and protein
(sub-)families.  control conditions for rats: experimental challenge with bacterial lipopolysaccharide (LPS); for penguins: all the inflammatory
non-Aspergillus diseases.
https://doi.org/10.1371/journal.pone.0200843.g003
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Table 3. List of the PANTHER pathways that were enriched during aspergillosis versus control situations. For
each species, enrichment was calculated in ratio with respect to the pathway representations reported in the reference
lists (http://www.geneontology.org/, as mentioned in the Material &Methods). Are shown below in the table only the
PANTHER pathways that were significantly enriched for at least one of the species studied (P<0.05).
Rat Penguin$
blood lung blood
5HT1 type receptor mediated signaling pathway 9.6
5HT2 type receptor mediated signaling pathway 4.0
5HT4 type receptor mediated signaling pathway 4.4
Alzheimer disease-amyloid secretase pathway 2.0
Alzheimer disease-presenilin pathway 1.1
Angiogenesis 2.2
Apoptosis signaling pathway 1.3
Axon guidance mediated by netrin 3.6
Axon guidance mediated by Slit/Robo 11.5
B-cell activation 1.8
Beta1 adrenergic receptor signaling pathway 3.4
Beta2 adrenergic receptor signaling pathway 3.5
Beta3 adrenergic receptor signaling pathway 5.5
Blood coagulation 11.9 4.1
Cadherin signaling pathway 1.4 1.1
CCKR signaling map 1.2
Cholesterol biosynthesis 11.5
Cytoskeletal regulation by Rho GTPase 2.6
De novo purine biosynthesis 19.1
DNA replication 13.8
Dopamine receptor mediated signaling pathway 2.5
EGF receptor signaling pathway 1.4
Endothelin signaling pathway 2.7
Enkephalin release 4.3
FGF signaling pathway 2.0 1.1
Fructose galactose metabolism 25.6
GABA-B receptor II signaling 4.1
General transcription by RNA polymerase I 8.2
Glycolysis 3.9 14.4
Hedgehog signaling pathway 10.3
Heme biosynthesis 12.8
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated
pathway
3.9
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated
pathway
2.1
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction 5.8
Histamine H1 receptor mediated signaling pathway 2.8
Histamine H2 receptor mediated signaling pathway 6.4
Huntington disease 1.2
Inflammation mediated by chemokine and cytokine signaling pathway 1.7
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade 5.8
Integrin signalling pathway 1.4
Interleukin signaling pathway 2.1
Ionotropic glutamate receptor pathway 2.6
(Continued)
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yield better rating in terms of the dynamic range of the analysis and microorganism specificity.
To address host protein changes during Aspergillus disease, our iTRAQ1 comparisons were
carried out in pooled samples from two distinct animal models, in order to reduce inter-indi-
vidual variabilities amongst each group and to increase the number of included specimens
[23]. Noteworthy, one should be aware that this approach limits how the global results can be
interpreted: specifically, it is indeed not possible to identify if the result from a single data
point–with aberrant value–is causing skewing of the entire dataset. However, this limitation
should not be a problem for the initial phase of screening, like in this preliminary work, espe-
cially if a confirmation technique is subsequently performed for individual measurements, like
trough ELISA assays, and if the animal models are quite homogenous like ours. Experimental
infection yields in the present study were similar to that previously reported >90% for rats
[19], although they nonetheless underscored the critical need for systematically verifying the
correct disease categorization by the means of several surrogate endpoints including galacto-
mannan antigen, fungal cultures, and histopathology [14,19]. To include relevant controls for
Table 3. (Continued)
Rat Penguin$
blood lung blood
Lipoate_biosynthesis 105.1
Lysine biosynthesis 98.1
Metabotropic glutamate receptor group I pathway 11.5
Metabotropic glutamate receptor group III pathway 1.9
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 4.7
Nicotine pharmacodynamics pathway 3.5
Nicotinic acetylcholine receptor signaling pathway
O-antigen biosynthesis 23.0
Opioid prodynorphin pathway 4.4
Opioid proenkephalin pathway 4.3
Oxidative stress response 2.3
Oxytocin receptor mediated signaling pathway 2.3
p38 MAPK pathway 3.1
p53 pathway 1.6
Parkinson disease
PDGF signaling pathway 2.7
Pentose phosphate pathway 14.4
PI3 kinase pathway
Pyruvate metabolism 47.8 16.4
Ras pathway 2.6
T-cell activation
Tricarboxylic acid cycle 52.1
TGF-beta signaling pathway 2.0 2.8
Thyrotropin-releasing hormone receptor signaling pathway 2.3
Ubiquitin proteasome pathway 6.4
VEGF signaling pathway 1.9
Wnt signaling pathway 3.9 1.3 1.9
 vs. bacterial lipopolysaccharides (LPS)-challenged control rats
$ vs. non-Aspergillus inflammatory control penguins
https://doi.org/10.1371/journal.pone.0200843.t003
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the proteomic analysis, a comparison of Aspergillus-infected rats with control rats experiencing
inflammation by bacterial endotoxin was performed [14], because the latter generates major
inflammation that can be observed with either lung infection or inhalation of toxic particles.
However, the infection induction mimics that in neutropenic human patients only, so that
conclusions should not be extended to non-neutropenic conditions [35]. Regarding penguins,
we rigorously enforced recruitment of miscellaneous controls which included various inflam-
matory processes and other non-aspergillosis infectious diseases. Nonetheless, one can notice
that the mean age in the control group is a little bit higher (P = 0.044), so than can introduce a
potential bias: this demographic discrepancy is due to the natural course of aspergillosis that is
rather acute, while most other control inflammatory diseases maybe occur more chronically.
The spectrum of all the proteins that were found differentially-represented during aspergil-
losis in rats and penguins showed major involvement of those with binding functions. Differ-
ences of protein expression were observed between fluids and tissues, suggesting distinct
metabolic patterns depending on the anatomic site of infection [36]. Additionally iTRAQ1
analysis underlined great expression differences, both qualitative and quantitative, between the
studied species: as illustrated previously in birds [37], penguins showed a lot of protein varia-
tions during aspergillosis, more than what was observed in our rat model. A possible explana-
tion relies in the immune status of penguins that were not neutropenic, on the contrary of the
rats of this study. Thus, they were probably more likely to develop anti-Aspergillus inflamma-
tory reaction, and this is maybe the particular reason why the interleukin (IL)-17 pathway was
particularly solicited in them [38]. However, it is noteworthy to report that three protein path-
ways were significantly enriched in both species studied, and so we decided to focus on them
because they appeared to play a common role during aspergillosis whatever the host: cadherin,
Wnt and FGF signaling pathways. Cadherin pathway is involved in cell adhesion by forming
adherens junctions to bind cells within tissues together [39]. The Wnt signaling pathway is an
ancient and evolutionarily conserved pathway that regulates crucial aspects of cell fate determi-
nation, cell migration, and cell polarity [40]. Wnt signal stimulates several intra-cellular signal
Fig 4. Scattergrams showing distribution of the individual measurements of Wnt1 inducible signaling pathway protein 1 (Wisp-1) and basic fibroblast growing
factor (bFGF) proteins in blood or in lung from the rat experimental model. A–Wisp-1 measurements in blood from 10 rats of each group. According to the kit
instructions, the detection ranged from 100 to 2,500pg/mL; B–Wisp-1 measurements in supernatants of the lung homogenates from 10 rats of each group; C–Basic FGF
measurements in supernatants of the lung homogenates from 10 rats of each group. The concentration gradients of the kit standards render a theoretical kit detection
range of 2–500 pg/mL through a standard curve using a vial of rat bFGF at 500 pg/mL as initial concentration. Abbreviation: LPS, bacterial lipopolysaccharide.
https://doi.org/10.1371/journal.pone.0200843.g004
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transduction cascades, including the canonical or Wnt/β-catenin dependent pathway and the
non-canonical or β-catenin-independent pathway [41]. It was shown that stimulation of Wnt/
β-catenin dependent pathway by agonist reduced aspartate aminotransferase, lactate, and lac-
tate dehydrogenase levels by 40%, 36%, and 77% six hours after an hemorrhagic shock gener-
ated in Sprague-Dawley rats [42]. Herein, we also confirmed by ELISA assay an
overexpression of the Wnt1-inducible-signaling pathway protein 1 (Wisp-1), also known as
CCN4 in humans, during experimental aspergillosis. Encoded by the WISP1 gene, Wisp-1 is a
secreted, extracellular matrix-associated signaling protein that is largely involved in the com-
mon Wnt pathway [43]. It can attenuate apoptosis and promote tissue growth and fibrosis. In
a previous study, neutralizing monoclonal antibodies specific tor Wisp-1 improved both lung
function and survival in a model of bleomycin-challenged C57BL/6N mice (+27%; P<0.02)
[44]. Once activated by secreted proteins of the signaling component of the FGF family, tyro-
sine kinase FGF receptors are able to phosphorylate specific tyrosine residues that thereafter
mediate interaction with cytosolic adaptor proteins and the RAS-MAPK (rat sarcoma—mito-
gen-activated protein kinase), PI3K-AKT (phosphoinositide 3-kinase–Ak thymoma), PLCγ
(phosphoinositide phospholipase Cγ), and STAT (signal transducers and activators of tran-
scription) intracellular signaling pathways [45]. Thus, FGF pathway plays a role during meta-
bolic disorders or in injured tissues, where it mediates metabolic functions, tissue repair, and
regeneration, often by reactivating developmental signaling pathways. A few years ago, cocktail
therapy combining FGF and Wnt inhibitors, such as small-molecule compounds and human
neutralizing antibodies, have been envisaged to increase the efficacy of anti-cancerous chemo-
therapy through the inhibition of recurrence by destructing cancer stem cells [46]. Besides
herein, genome ontology enrichment analysis showed significant over-involvement of blood
coagulation cascade in the rat model that means several proteins of this process were signifi-
cantly overproduced during aspergillosis, perhaps following initial consumption or proteolysis
as a consequence of angio-invasion. If we extrapolate this finding to neutropenic humans, one
can reasonably speculate this may have consequences on hemorrhagic risks and the occur-
rence of episodes of disseminated intravascular coagulation, highlighting the need to thor-
oughly monitor the hemostasis of Hematology patients. Relative increase of several leucine-
rich glycoproteins and their derivatives were confirmed by 2.0-fold in rat lungs, 2.6- and
2.0-fold in penguins, as previously reported with 1.4-fold increase in human samples [18].
Although their actual role in promoting host-fungal invasion has not been totally elucidated,
leucine-rich glycoproteins have been described as involved in cellular adhesion [47]. Likewise,
demonstration of increased secretion of host proteins that control the metabolic processes, like
extracellular proteinases and ribonucleotoxin was confirmed herein by our iTRAQ1 protocol
results [14]: for example, serine peptidase inhibitor clade B member 1b was 3.1-fold overrepre-
sented in rat blood and serine peptidase inhibitor clade A member 3B (alpha-1 antiproteinase,
antitrypsin) was 2.1-fold increased in rat lungs. Alpha-1-acid glycoprotein, also referred to as
orosomucoid, was measured 2.3-fold increased in infected rat lungs, which was consistent
with its in situ immune-modulating effects [48]. Expression of the alpha-1-acid glycoprotein
gene is controlled by a combination of the major regulatory mediators, i.e. a pro-inflammatory
cytokine network involving mainly IL-1 beta, tumor necrosis factor-alpha, IL-6 and other IL-6
related cytokines, which have been all described in immune response against Aspergillus [49].
As interleukin-inhibitors have been proven to be useful in some autoimmune diseases [50],
one could consider on the contrary the benefit of drugs stimulating the aforementioned com-
ponents for the struggle against Aspergillus fungus. Surprisingly, inter-alpha-trypsin inhibitor
heavy-chain, ITIH4 i.e. a α1-globulin, was found 2.0-lowered in penguins of this study,
whereas it was shown to be approximately 1.7- to 8.5-fold upregulated in Aspergillus-diseased
rats in our previous work which was based on 2D-gel electrophoresis as pre-MS screening
iTRAQ protocol for investigation of aspergillosis
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[14]. Regarding specifically the proteins involved in the lipid metabolism, several apolipopro-
teins have been reported in other models of aspergillosis which is likely related to their well-
known antioxidant and anti-inflammatory properties [51]. Herein, apolipoprotein AII and
apolipoprotein E were 2.2- and 2.1-fold enriched in diseased rat lungs vs. LPS-control lungs,
respectively. Both have already been reported 4.0- and 5.8-fold increased in rat BALF [14]. In
human blood obtained from leukemic patients with aspergillosis, Brasier et al. showed a
1.6-fold decrease of apolipoprotein AII, suggesting a local consumption during tissue invasion
[18]. In the present study, eight other proteins related to lipid synthesis or transport were also
found with significant changes vs. control conditions, like lipid phosphate phosphatase-related
protein type 3 in penguins, as well as several phospholipases. For therapeutic purposes, a few
short molecules have been recently developed to moderate lipoprotein levels and so they can
be valuable to test during aspergillosis [52]. Zinc finger proteins were decreased in both animal
species of this study, i.e. 5.4- and 7.5-fold in rats and penguins, respectively.
Interestingly, our MS findings sometimes contradicted previous studies [18,53]. For exam-
ple, we failed to prove that the involvement of the individual components of complement cas-
cade was significant during aspergillosis, except for complement C8 in rat lungs (2.5-fold
increase vs. LPS-control lungs). This finding may indicate that complement components are
eventually not so crucial for innate defense against Aspergillus and future therapeutic
approaches should not only focus on them. Similarly, previous MS approaches defined major
changes in various fibrinogen isoforms [18], that have been assumed to play a role in promot-
ing cell adhesion once induced by IL-6 [54]. This hypothesis was not confirmed herein, per-
haps because our protein identification was based on very stringent statistics and thus avoided
fibrinogen misidentification. Likewise except for ITIH4 protein, [8,22], no significant changes
were reported for some specific proteins belonging to α1-, α-2 and β-globulins. This suggests
that conventional plasma protein electrophoresis analysis only addresses global changes for
each protein moiety [8,55]; the moieties should be considered as the sum of slight–and often
insignificant–individual changes [18]).
Overall, use of the iTRAQ1 protocol present study provided new insights into host inflam-
matory response against Aspergillus in two relevant infection models. One could just consider
these MS findings as preliminary trials for better understanding pathophysiology of aspergillo-
sis, like demonstrated by the common increase of the cadherin, Wnt and FGF signaling path-
ways. Thus, MS has probably the potential to further refine diagnostics or to suggest
therapeutic targets and monitoring markers. Additional studies are now needed to validate
these results and expand on the construction of functional protein networks during aspergillo-
sis. This example of iTRAQ1 protocol application should be easily reproduced in other spe-
cies, like humans, and in other diseases.
Supporting information
S1 Table. Summary of the global protein changes observed by iTRAQ1 protocol-based
mass spectrometry analysis. Only the relative changes that were statistically significant versus
controls are reported below (for details, see Material & Methods section). Results are expressed
in absolute numbers and in percentage for the representative proportion with respect to the
total number of proteins identified for each species in GO databases (http://www.
geneontology.org/) (between brackets).
(DOCX)
S2 Table. Raw data of mass spectrometry analysis. This supplementary material displays the
exhaustive listing of all the proteins that have been identified in rats, penguins and humans.
(XLSX)
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